Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 December 2023 | Story LUNGA LUTHULI | Photo SUPPLIED
Milton Mogotsi
Charting unexplored territories: Milton Mogotsi, UFS PhD student, clinches victory in National 3MT Competition, unravelling infant enteric virome complexities, poised to revolutionise virology.

Milton Mogotsi, a PhD student at the University of the Free State (UFS), has secured a remarkable victory in the esteemed National 3 Minute Thesis competition (3MT), rising above formidable competition nationwide. This achievement follows Mogotsi’s earlier successes at faculty and institutional levels, where his presentations on the enteric virome of infants in the Free State stood out for their brilliance and significance.

The annual competition serves as a platform for postgraduate students to enhance their academic, presentation, and research communication skills by succinctly explaining their research to an intelligent but non-specialist audience within a concise 3-minute timeframe.

Reflecting on his initial reaction to the news, Mogotsi expressed a mix of shock and excitement. “I was genuinely shocked and excited when declared the winner,” he shared. This victory marked a significant milestone for Mogotsi, as a first-time participant, showcasing the excellence of both the UFS and the Faculty of Health Sciences.

Exploring uncharted territories

Mogotsi’s groundbreaking research delves into the unexplored domain of the enteric virome in infants, a subject inspired by his earlier master’s study in microbiology. “I was first introduced to this research during my master’s degree, and compelling findings motivated me to pursue further studies,” explained Mogotsi. Guided by his mentor, Prof Martin Nyaga, Mogotsi's doctoral journey unfolded into a profound exploration of the complexities of viruses colonising infants' guts and their implications on infant health.

Sharing key findings, Mogotsi highlighted that, despite detecting several disease-causing viruses in infants’ guts, none exhibited clinical symptoms. This emphasises the role of immunity and protective measures like breastfeeding. He also identified plant viruses, potentially transmitted through the environment or food sources, raising intriguing questions about infants’ exposure.

His pioneering use of viral metagenomics in unravelling the enteric virome’s complexity underscored its potential in understanding human health and disease. “Viral metagenomics has become a fundamental tool, shedding light on the composition of the infant’s enteric virome,” explained Mogotsi. 

Navigating challenges

Despite challenges, including disruptions due to COVID-19 and participant withdrawals, Mogotsi persevered, underscoring the importance of a longitudinal approach in comprehending the infant virome’s development over time. His success in the competition not only boosted his confidence but also expanded his networks, providing invaluable opportunities to present his findings internationally.

Mogotsi's advice to aspiring researchers mirrors his own journey: clarity of purpose, resilience in the face of challenges, fostering mentor relationships, and making the most of available resources. His groundbreaking work is poised to influence policy, guide vaccine strategies, and reshape our understanding of infant health.

As Mogotsi approaches the completion of his PhD, the future holds promising horizons for this trailblazing researcher, poised to leave an indelible mark on the world of virology and infant health.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept